X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Divis Laboratories with ALEMBIC LTD - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs ALEMBIC LTD - Comparison Results

DIVIS LABORATORIES    Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

ALEMBIC LTD 
   Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES ALEMBIC LTD DIVIS LABORATORIES/
ALEMBIC LTD
 
P/E (TTM) x 38.5 58.2 66.1% View Chart
P/BV x 6.2 2.4 256.8% View Chart
Dividend Yield % 0.7 0.4 171.3%  

Financials

 DIVIS LABORATORIES   ALEMBIC LTD
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-18
ALEMBIC LTD
Mar-18
DIVIS LABORATORIES/
ALEMBIC LTD
5-Yr Chart
Click to enlarge
High Rs1,14272 1,585.8%   
Low Rs53334 1,572.6%   
Sales per share (Unadj.) Rs146.64.7 3,118.5%  
Earnings per share (Unadj.) Rs33.06.1 541.3%  
Cash flow per share (Unadj.) Rs38.46.2 614.9%  
Dividends per share (Unadj.) Rs10.000.20 5,000.0%  
Dividend yield (eoy) %1.20.4 316.1%  
Book value per share (Unadj.) Rs222.840.7 548.0%  
Shares outstanding (eoy) m265.47267.03 99.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.711.3 50.7%   
Avg P/E ratio x25.38.7 292.2%  
P/CF ratio (eoy) x21.88.5 257.2%  
Price / Book Value ratio x3.81.3 288.6%  
Dividend payout %30.33.3 923.8%   
Avg Mkt Cap Rs m222,31814,139 1,572.3%   
No. of employees `00010.8NA-   
Total wages/salary Rs m4,561207 2,198.9%   
Avg. sales/employee Rs Th3,616.0NM-  
Avg. wages/employee Rs Th423.8NM-  
Avg. net profit/employee Rs Th814.9NM-  
INCOME DATA
Net Sales Rs m38,9151,255 3,100.3%  
Other income Rs m1,134370 306.4%   
Total revenues Rs m40,0491,625 2,464.0%   
Gross profit Rs m12,617111 11,356.5%  
Depreciation Rs m1,42538 3,769.6%   
Interest Rs m132 782.4%   
Profit before tax Rs m12,313442 2,787.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m01,212 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,54324 14,794.2%   
Profit after tax Rs m8,7701,630 538.1%  
Gross profit margin %32.48.9 366.3%  
Effective tax rate %28.85.4 530.8%   
Net profit margin %22.5129.8 17.4%  
BALANCE SHEET DATA
Current assets Rs m45,3511,867 2,429.0%   
Current liabilities Rs m6,507591 1,100.7%   
Net working cap to sales %99.8101.6 98.2%  
Current ratio x7.03.2 220.7%  
Inventory Days Days12794 134.4%  
Debtors Days Days9574 129.4%  
Net fixed assets Rs m21,1601,791 1,181.5%   
Share capital Rs m531534 99.4%   
"Free" reserves Rs m58,62510,324 567.9%   
Net worth Rs m59,15610,858 544.8%   
Long term debt Rs m041 0.0%   
Total assets Rs m67,83211,591 585.2%  
Interest coverage x926.8260.9 355.3%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.60.1 529.8%   
Return on assets %12.914.1 92.0%  
Return on equity %14.815.0 98.8%  
Return on capital %20.815.2 137.2%  
Exports to sales %01.5 0.0%   
Imports to sales %21.821.0 103.9%   
Exports (fob) Rs mNA19 0.0%   
Imports (cif) Rs m8,485263 3,222.1%   
Fx inflow Rs m32,35919 166,799.0%   
Fx outflow Rs m9,042264 3,427.5%   
Net fx Rs m23,317-244 -9,539.6%   
CASH FLOW
From Operations Rs m7,759236 3,290.3%  
From Investments Rs m-4,783-224 2,135.3%  
From Financial Activity Rs m-3,142-27 11,810.5%  
Net Cashflow Rs m-166-15 1,121.6%  

Share Holding

Indian Promoters % 52.0 64.0 81.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.8 0.2 5,900.0%  
FIIs % 19.0 9.7 195.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.2 26.1 65.9%  
Shareholders   31,796 54,701 58.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   ABBOTT INDIA  JUBILANT LIFE SCIENCES  DISHMAN PHARMA  PIRAMAL ENTERPRISES  NATCO PHARMA  

Compare DIVIS LABORATORIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 170 Points Lower, Realty and FMCG Stocks Witness Selling(Closing)

After opening the day on a positive note, share markets in India witnessed volatile trading activity and ended in red.

Related Views on News

BIOCON LTD at All Time High; BSE HEALTHCARE Index Up 0.7% (Market Updates)

Sep 19, 2018 | Updated on Sep 19, 2018

BIOCON LTD share price has hit an all time high at Rs 695 (up 1.6%). The BSE HEALTHCARE Index is up by 0.7%. Among the top gainers in the BSE HEALTHCARE Index today are BIOCON LTD (up 1.6%) and SANOFI INDIA (up 0.4%). The top losers include PIRAMAL ENTERPRISES and LUPIN LTD (down 0.1%).

DIVIS LABORATORIES at All Time High; BSE HEALTHCARE Index Up 1.2% (Market Updates)

Sep 19, 2018 | Updated on Sep 19, 2018

DIVIS LABORATORIES share price has hit an all time high at Rs 1,406 (up 1.8%). The BSE HEALTHCARE Index is up by 1.2%. Among the top gainers in the BSE HEALTHCARE Index today are DIVIS LABORATORIES (up 1.8%) and SANOFI INDIA (up 0.4%). The top losers include ABBOTT INDIA (down 0.1%) and ALEMBIC PHARMA (down 0.2%).

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

In a Crisis, if Petrol Prices Hit Rs 100, This Stock Could Be a Good Buy(The 5 Minute Wrapup)

Sep 6, 2018

The rise in the crude oil price is a major reason for the fall in the market. If crude oil prices keep on rising, what will happen to stocks?

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

Hurricanes Threaten Oil Spike, but the Saudis are Selling...(Vivek Kaul's Diary)

Sep 6, 2018

Oil prices are rising and could go even more higher amid rising tensions in Middle East.

Should You Be Worried About the Rising Dollar?(Chart Of The Day)

Sep 7, 2018

While the rupee has deprecated by about 5% annually since 1990 against the dollar, the BSE Sensex has returned 14% annually in the same period.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Sep 19, 2018 03:37 PM

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES - ASTRAZENECA PHARMA COMPARISON

COMPARE DIVIS LABORATORIES WITH

MARKET STATS